Page 1 | Search Results | Blood | American Society of Hematology

1-12 of 12

Sort by

Sort Order Select

Journal Articles

Low Dose Total Body Irradiation Improves CD19 CAR-T Expansion, Persistence, and Trafficking, Leading to Enhanced Efficacy in Large B-Cell Lymphoma

Mohammad Alhomoud, Michelle Foley, Mayumi Sugita, Takahiro Yamazaki, Leandro Martinez, Samuel Yamshon, Alexandra Gomez-Arteaga, Paul Pagnini, Tsiporah B. Shore, Olivier Boyer, Renier Brentjens, Koen Van Besien, Lorenzo Galluzzi, Silvia Formenti, Jeremie Martinet, Monica L. Guzman

Blood (2023) 142 (Supplement 1): 1016.

https://doi.org/10.1182/blood-2023-185216

Published: 2023

Journal Articles

Low-Dose Radiation Improves Anti-CD19 CAR T-Cells Efficacy in Diffuse Large B-Cell Lymphoma through Fas/FasL Pathway

Mohammad Alhomoud, Jeremie Martinet, Mayumi Sugita, Takahiro Yamazaki, Olivier Boyer, Lorenzo Galluzzi, Silvia C Formenti, Koen Van Besien, Monica L. Guzman

Blood (2022) 140 (Supplement 1): 4519–4520.

https://doi.org/10.1182/blood-2022-169356

Published: 2022

Journal Articles

Diffuse Large B Cell Pdtx in Humanized Mice Are Valuable Models to Study Host-Lymphoma Interactions and Immune-Modulating Agents

Giorgia Zanetti, Giuseppina Astone, Luca Cappelli, William Chiu, Maria Teresa Cacciapuoti, Clarisse Kayembe, Danilo Fiore, Wayne Tam, Joseph Scandura, Silvana Di Giandomenico, Lorenzo Galluzzi, Lisa Giulino Roth, Giorgio Inghirami

Blood (2021) 138 (Supplement 1): 2406.

https://doi.org/10.1182/blood-2021-151598

Published: 2021

Journal Articles

Composite Copy Number Variation in CDK4 , CDKN2A and RB1 Predisposes Mantle Cell Lymphoma to Expansion of PD1+ Tumor Cells and Resistance to CDK4/6 Inhibitor Therapy as Revealed by Integrative Longitudinal scRNA-seq

Maurizio Di Liberto, PhD, Yang Hu, PhD, Xiangao Huang, PhD, Christina Y. Lee, MD, Kevin Wang, B.S., Nancy L. Bartlett, MD, LeAnn Ridling, Kristie A. Blum, MD, Kami J. Maddocks, MD, Steven I Park, MD, Jia Ruan, MD PhD, Kenneth Eng, B.S., Lorenzo Galluzzi, PhD, John P. Leonard, MD, Peter Martin, FRCPC, MD MS, Olivier Elemento, PhD, Selina Chen-Kiang, PhD

Blood (2019) 134 (Supplement_1): 1492.

https://doi.org/10.1182/blood-2019-130944

Published: 2019

Journal Articles

T-Cell Clonal Expansion and Activation Associated with Durable Clinical Response to Dual BTK and CDK4/6 Inhibitor Therapy in Mantle Cell Lymphoma

Christina Y. Lee, MD, Maurizio Di Liberto, PhD, Yang Hu, PhD, Xiangao Huang, PhD, Nancy L Bartlett, MD, Kami J. Maddocks, MD, John P. Leonard, MD, Nils-Petter Rudqvist, PhD, Lorenzo Galluzzi, PhD, Peter Martin, FRCPC, MD MS, Olivier Elemento, PhD, Selina Chen-Kiang, PhD

Blood (2019) 134 (Supplement_1): 3973.

https://doi.org/10.1182/blood-2019-122322

Published: 2019

Journal Articles

Calreticulin exposure by malignant blasts correlates with robust anticancer immunity and improved clinical outcome in AML patients

Jitka Fucikova, Iva Truxova, Michal Hensler, Etienne Becht, Lenka Kasikova, Irena Moserova, Sarka Vosahlikova, Jana Klouckova, Sarah E. Church, Isabelle Cremer, Oliver Kepp, Guido Kroemer, Lorenzo Galluzzi, Cyril Salek, Radek Spisek

Blood (2016) 128 (26): 3113–3124.

https://doi.org/10.1182/blood-2016-08-731737

Published: 2016

Includes: Supplemental data

Journal Articles

Increased Proliferation Induced by Constitutive Activation of the Src-Kinase Lyn and Aberrant mTOR Signaling in AML Is Abrogated by the EGFR-Inhibitor Erlotinib.

Simone Boehrer, MD, PhD, Lorenzo Galluzzi, phD, Lionel Ades, MD, Celine Fouassier, Claude Gardin, MD, Pierre Fenaux, MD, PhD, Guido Kroemer, MD, PhD

Blood (2009) 114 (22): 3813.

https://doi.org/10.1182/blood.V114.22.3813.3813

Published: 2009

Journal Articles

The Capacity of the Hypomethylating Agents Azacytidine and Decitabine to Induce Apoptosis and Cell Cycle Arrest Depends on the Activation of the DNA-Damage Response Pathway.

Simone Boehrer, Lionel Ades, Nicolas Tajeddine, Lorenzo Galluzzi, Stephane de Botton, Pierre Fenaux, Guido Kroemer

Blood (2008) 112 (11): 1655.

https://doi.org/10.1182/blood.V112.11.1655.1655

Published: 2008

Journal Articles

Selective Suppression of the DNA Damage Response in Acute Myeloid Leukemia Versus Myelodysplastic Syndrome.

Simone Boehrer, Lionel Ades, Nicolas Tajeddine, Lorenzo Galluzzi, Wolf-Karsten Hofmann, Pierre Fenaux, Guido Kroemer

Blood (2008) 112 (11): 1656.

https://doi.org/10.1182/blood.V112.11.1656.1656

Published: 2008

Journal Articles

Erlotinib exhibits antineoplastic off-target effects in AML and MDS: a preclinical study

Simone Boehrer, Lionel Adès, Thorsten Braun, Lorenzo Galluzzi, Jennifer Grosjean, Claire Fabre, Génèviève Le Roux, Claude Gardin, Antoine Martin, Stéphane de Botton, Pierre Fenaux, Guido Kroemer

Blood (2008) 111 (4): 2170–2180.

https://doi.org/10.1182/blood-2007-07-100362

Published: 2008

Includes: Supplemental data

Journal Articles

The EGFR-Inhibitor Erlotinib Induces Differentiation, Cell Cycle Arrest and Apoptosis in EGFR-Negative Cells of MDS and AML.

Simone Boehrer, MD, Lionel Ades, MD, Thorsten Braun, MD, Lorenzo Galluzzi, Jennifer Grosjean, Claire Fabre, MD, Genevieve Le Roux, Claude Gardin, MD, Antoine Martin, MD, Stephane de Botton, MD, Pierre Fenaux, MD, PhD, Guido Kroemer, MD, PhD

Blood (2007) 110 (11): 399.

https://doi.org/10.1182/blood.V110.11.399.399

Published: 2007

Journal Articles

Further Evidence That MDS and AML Cells Exhibit a Differential Capacity To Activate the DNA-Damage Response (DDR) Pathways.

Simone Boehrer, MD, Lionel Ades, MD, Lorenzo Galluzzi, Ken Olaussen, PhD, Thorsten Braun, MD, Jennifer Grosjean, PhD, Claire Fabre, MD, Stephane de Botton, MD, Pierre Fenaux, MD, PhD, Guido Kroemer, MD, PhD

Blood (2007) 110 (11): 2438.

https://doi.org/10.1182/blood.V110.11.2438.2438

Published: 2007

NARROW

Low Dose Total Body Irradiation Improves CD19 CAR-T Expansion, Persistence, and Trafficking, Leading to Enhanced Efficacy in Large B-Cell Lymphoma

Low-Dose Radiation Improves Anti-CD19 CAR T-Cells Efficacy in Diffuse Large B-Cell Lymphoma through Fas/FasL Pathway

Diffuse Large B Cell Pdtx in Humanized Mice Are Valuable Models to Study Host-Lymphoma Interactions and Immune-Modulating Agents

Composite Copy Number Variation in CDK4 , CDKN2A and RB1 Predisposes Mantle Cell Lymphoma to Expansion of PD1+ Tumor Cells and Resistance to CDK4/6 Inhibitor Therapy as Revealed by Integrative Longitudinal scRNA-seq

T-Cell Clonal Expansion and Activation Associated with Durable Clinical Response to Dual BTK and CDK4/6 Inhibitor Therapy in Mantle Cell Lymphoma

Calreticulin exposure by malignant blasts correlates with robust anticancer immunity and improved clinical outcome in AML patients

Increased Proliferation Induced by Constitutive Activation of the Src-Kinase Lyn and Aberrant mTOR Signaling in AML Is Abrogated by the EGFR-Inhibitor Erlotinib.

The Capacity of the Hypomethylating Agents Azacytidine and Decitabine to Induce Apoptosis and Cell Cycle Arrest Depends on the Activation of the DNA-Damage Response Pathway.

Selective Suppression of the DNA Damage Response in Acute Myeloid Leukemia Versus Myelodysplastic Syndrome.

Erlotinib exhibits antineoplastic off-target effects in AML and MDS: a preclinical study

The EGFR-Inhibitor Erlotinib Induces Differentiation, Cell Cycle Arrest and Apoptosis in EGFR-Negative Cells of MDS and AML.

Further Evidence That MDS and AML Cells Exhibit a Differential Capacity To Activate the DNA-Damage Response (DDR) Pathways.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only